Related Experiment Video

Updated: Feb 3, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.0K

Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents

Maricruz Anaya-Ruiz1, Cindy Bandala2, Gerardo Landeta3

  • 1Cell Biology Laboratory, Biomedical Research Center of the East, Mexican Institute of Social Security, Metepec, Puebla CP 74360, Mexico.

Recent Patents on Anti-Cancer Drug Discovery
|November 2, 2018
PubMed
Abstract

Insights

Researchers analyzed patents for nanostructured drug delivery systems to improve cancer treatment. Recent developments show a focus on nanoparticles like nanodiscs, gold nanoparticles, and immunoliposomes for enhanced cancer therapy.

Area of Science:

  • Biotechnology
  • Nanotechnology
  • Oncology

Background:

  • Cancer remains a leading global cause of death.
  • Current cancer therapies face challenges with tumor accessibility, efficacy, and toxicity.
  • Novel treatment strategies are crucial for effective cancer management.

Purpose of the Study:

  • To identify and analyze recent patents for nanostructured drug delivery systems in cancer treatment.
  • To understand the landscape of innovation in nanomedicine for oncology.

Main Methods:

  • A comprehensive patent search was conducted across six major global patent offices.
  • Keywords used included 'drug delivery nanostructured systems for cancer treatment'.
  • Patent documents from 1998 to 2017 were analyzed.

Main Results:

  • 1710 patent documents were retrieved, indicating significant research activity.
  • The USA, China, and South Korea lead in patent filings for these systems.
  • US and Chinese institutions show the highest patent contributions.

Conclusions:

  • There is a clear trend towards developing advanced nanostructured systems for drug delivery.
  • Recent innovations concentrate on specific nanoparticle types such as nanodiscs, gold nanoparticles, and immunoliposomes.
  • These nanomedicine advancements hold promise for improving cancer treatment outcomes.
Keywords:
Cancerdeliveringdrugnanostructurespatenttherapy.

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.6K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.3K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
833
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
519
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
714